Cyrus Moza­yeni fol­lows ADC 'bea­con' to Pheon CEO role; BeiGene los­es busi­ness chief to Te­va

Cyrus Moza­yeni has been around the biotech busi­ness long enough not to be fazed when things don’t go as ex­pect­ed.

Soon af­ter he closed his last start­up in April, Vedere Bio II — a gene ther­a­py biotech born out of an­oth­er that was sold to No­var­tis — he re­turned to his net­work at At­las Ven­ture, where he is en­tre­pre­neur-in-res­i­dence, to scout new op­por­tu­ni­ties. Ear­li­er this month, he start­ed a new job as CEO of Pheon Ther­a­peu­tics to re­place Bertrand Damour at the At­las-backed com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER